Clinical Trial Update: Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED) [Phase 2]

View source ↗

Summary

This Phase 2 study evaluated boceprevir in combination with pegylated interferon alfa-2b, with or without added ribavirin, in patients with chronic hepatitis C …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Boceprevir (boceprevir)
• PEG Intron (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2011-12-29